ArticleJACC. Case reports2026
CT-Guided Lipid-Lowering Therapy Leading to Functional Resolution of Ischemia.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAggressive lipid-lowering therapy may lead to regression of atherosclerosis; there are scarce data supporting such an approach for improving coronary physiological indexes. Serum low-density lipoprotein cholesterol is the primary target for lipid-lowering therapy. Computed tomography (CT)-derived assessments of plaque composition and coronary physiology are promising targets for individualized lipid-lowering strategies. CASE SUMMARY: A 62-year-old woman presented with intermittent angina on moderate exertion. Coronary CT angiography revealed a significant focal stenosis in the left circumflex artery (fractional flow reserve based on CT [FFR DISCUSSION: This case demonstrates that CT-guided lipid-lowering therapy can reverse plaque burden and ischemia in a patient with a flow-limiting epicardial lesion. The therapeutic targets proposed here, addressing both morphological plaque characteristics and coronary physiology parameters, go beyond the traditional goal of lowering low-density lipoprotein cholesterol levels. Pharmacological strategy guided by precise plaque imaging and functional assessment requires confirmation in larger clinical studies. TAKE-HOME MESSAGE: CT-guided pharmacotherapy aimed at improving both plaque composition and epicardial coronary flow parameters may represent an alternative to uniform treatment strategies based on cholesterol levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.